Should we treat HIV Controllers ? IAS 2013 Pr Olivier Lambotte Department of internal medicine and clinical immunology Bicêtre Hospital, University Paris.

Slides:



Advertisements
Similar presentations
New concepts in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference Nicolas Chomont VGTI-Florida.
Advertisements

Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway
CHER Trial: Early Antiretroviral Therapy and Mortality Among HIV- Infected Infants New England J Med 2008;359 (21):
Using longitudinal, population-based HIV surveillance to measure the real-world impacts of ART scale-up in KwaZulu- Natal, South Africa Frank Tanser Presentation.
Monica Gandhi MD, MPH Associate Professor and Women’s HIV Clinic provider, HIV/AIDS Division San Francisco General Hospital/ UCSF Safe Poz Love, U.S. Positive.
Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium.
HLA-B57 does not fully explain the ability of HIV controllers to clear HCV infection Alice K. Asher 1, RN, MS; Glenn-Milo Santos 1, MPH; Jennifer Evans,
The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.
Natural and induced control of HIV infection: differences and similarities VISCONTI Study Asier Sáez-Cirión, PhD Unité de Régulation des Infections Rétrovirales.
Slide 1 of 11 From CB Hicks, MD, at Chicago, IL: May 20, 2013, IAS-USA. IAS–USA Charles B. Hicks, MD Professor of Medicine Duke University Medical Center.
Virologic and immunologic response following antiretroviral therapy initiation among pregnant and postpartum women with acute HIV-1 infection: MOPDB0101.
Professeur Patrice DEBRE Laboratoire d’Immunologie Cellulaire et Tissulaire INSERM U945 Hôpital Pitié-Salpêtrière; Paris "Vers un vaccin contre le SIDA.
Why is inflammation elevated in treated HIV infection and why does it matter? Steven G. Deeks Professor of Medicine University of California, San Francisco.
Immune Reconstitution Inflammatory Syndrome (IRIS)
Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,
EARLY ANTIRETROVIRAL TREATMENT HIV Cure Research Training Curriculum (CUREiculum) Early Antiretroviral (ART) Treatment Module by: Scientific Leads: Dr.
Current HIV basic science research topics. Toddler "Functionally Cured" of HIV Infection- “the Mississippi Baby” First well-documented case of an HIV.
Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.
Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma Marcelin AG 1, Tubiana R 1, Lambert-Niclot.
HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial James Williams 1,2,3, Jacob Hurst 1,2,3,
Validating five questions of antiretroviral non-adherence in a decentralized public-sector antiretroviral treatment program in rural South Africa Krisda.
Eric S. Rosenberg, M.D. Associate Professor of Medicine Massachusetts General Hospital Harvard Medical School
Is monitoring for CD4 counts still needed for the management of patients with long- term HIV RNA suppression? Andrew Hill, Liverpool University, UK.
Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy S. Fourati 1, R. Calin 2, G. Carcelain 3, P.
Rémi Cheynier Victor Appay Anne Hosmalin Gianfranco Pancino Vincent Vieillard Brigitte Autran Françoise Brun-Vezinet Charlotte Charpentier Diane Descamps.
1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Slide 1 of 11 From DA Wohl, MD, at New York, NY: May 03, 2012, IAS-USA. IAS–USA David Alain Wohl, MD Associate Professor of Medicine The University of.
Global HIV Resistance: The Implications of Transmission
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.
Naive CD4 T lymphocytes and recent thymic emigrants, 15 or more years after perinatal HIV infection The ANRS-EP38-IMMIP study Stéphane Blanche, Daniel.
Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Sulggi Lee, M.D., Ph.D. Assistant Professor of Medicine University of California,
HIV-1 infected subjects treated with an autologous dendritic cell therapy (AGS-004), exhibited a significant reduction in viral load (when compared to.
Effect of 24 Week Intensification with a CCR5-Antagonist on the Decay of the HIV-1 Latent Reservoir IAS HIV RESERVOIRS WORKSHOP, 16 & 17 JULY 2010, VIENNA.
Challenges to replacing CD4 testing with viroloigical monitoring Andrew Hill, Pharmacology Research Laboratories, University of Liverpool, UK World AIDS.
Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.
Immigration Removal Centres and HIV Clinical Care Jane Anderson Homerton University Hospital NHS Foundation Trust.
The Use of Pooled Viral Load Testing to Identify Antiretroviral Treatment Failure Davey Smith 1, Susanne May 2, Josué Perez-Santiago 1, Matthew Strain.
Kuala Lumpur, Malaysia, 30 June - 3 July 2013 In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500.
HBV related complications in HIV positive patients during HAART therapy Irina Magdalena Dumitru*, E. Dumitru*, S. Rugina*, Roxana Carmen Cernat**, Simona.
ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.
The effect of tuberculosis treatment on virologic and immunologic response to combination antiretroviral therapy among South African children Heidi M.
12th Conference on Retroviruses and Opportunistic Infections February 22-25, 2005 Boston, Massachusetts, USA Poster No. 830 Hematological Benefit of Switching.
Potential Utility of Tipranavir in Current Clinical Practice Daniel R. Kuritzkes, MD Director of AIDS Research Brigham and Woman’s Hospital Division of.
1 Adherence to ARV Therapy and Resistance HAIVN Havard Medical School AIDS Initiative in Vietnam.
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
T-cell activation positively correlates with cell-associated HIV-DNA level in PBMCs in viremic patients with acute or chronic HIV-1 infection Laurence.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Major Changes to the HHS Adult and Adolescent HIV Treatment Guidelines: April 2015 Brian R. Wood, MD.
Isolated Hepatitis B Core Antibody
Figure 2: Trends in currently prescribed antiretroviral therapy % prescribed HAART increased from 74% to 83% Trends in ART use, HIV viral load, and CD4.
Time to HAART Resume after Structured Treatment Interruption is Strongly Associated with HIV DNA Level in PBMC at Interruption: Results of the ANRS 116.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
Short-Term Efficacy and Tolerance of ddI, 3TC, EFV regimen Once-Daily in HIV-1–Infected African Children: ANRS (Burkiname). Operational lessons from.
Long-term clinical and viro-immunologic outcomes of post-treatment controllers (PTCs) in the ANRS-VISCONTI study Laurent HOCQUELOUX, MD Orléans’ Regional.
Diego Ripamonti - Malattie Infettive - Bergamo Simposio HOT TOPICS Hot topics in HIV 2015.
1 Predictors of virological failure in a Cambodian setting Sokkab An, M.D Sihanouk Hospital Center of HOPE (SHCH), Phnom Penh, Cambodia.
This presentation is intended for educational use only, and does not in any way constitute medical consultation or advice related to any specific patient.
Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.
Session Code: MOAA01, Abstract #MOAA0103
Catherine K. Koofhethile 21st IAS July,2016 Durban, SA
Acceptability of early HIV treatment among South Africa women N Garrett, E Norman, V Asari, N Naicker, N Majola, K Leask, Q Abdool Karim and SS Abdool.
and HIV Controllers Kuala Lumpur, 2nd July 2013
HIV Cure: Current Status and Future Perspectives
HEATHER Feedback Meeting
Coinfection With HIV-1 and HCV—A One-Two Punch
Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers by Asier Sáez-Cirión, Chiraz Hamimi, Anna Bergamaschi, Annie David,
Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load by Steven G. Deeks, Christina.
The block-and-lock approach
Residual Disease and Immune Activation/Inflammation on ART
Coinfection With HIV-1 and HCV—A One-Two Punch
Presentation transcript:

Should we treat HIV Controllers ? IAS 2013 Pr Olivier Lambotte Department of internal medicine and clinical immunology Bicêtre Hospital, University Paris South

International guidelines for anti-retroviral treatment USA (NIH) ANRS European AIDS Clinical Society International AIDS Society = ART is recommended for all HIV-1 infected patients Reasons: -To block viral replication leads to immune reconstitution with CD4 T cell increase -Control of HIV leads to reduced immune activation and its consequences (immunological and clinical) -To block viral replication leads to reduced HIV transmission

What would be the reasons to treat a HIV controller ? HIV controllers can be considered as a model of functional cure...

What would be the reasons to treat a HIV controller ? Viral replication ? Decrease of the CD4 T cell count ? Both ? What’s about the role of immune activation and chronic inflammation in these patients ?

Viral replication Viral escape (Sajadi et al. JAIDS 2009, Rachinger CID 2008) –A rare event which should question a superinfection (Sajadi et al. JAIDS 2009, Rachinger CID 2008) –Controllers are able to control burst of viral replication (Rachinger et al) –On a 4-year period, in the French cohort (220 patients), 5 « viral escapes » with two consecutive VL > 2000 RNA copies/mL –Only 2 are treated, the 3 others became « viremic controllers »

Viral replication The virus –It can be a reason to treat a controller BUT viral replication is present in all (?) controllers There is a low-grade viral replication in all (?) controllers (range  ART-treated patients [1-10 RNA copies/mL] –Hatano et al. (J Virol 2009): longitudinal follow-up 45/46 patients HIC had  1 detectable usVL -CO21 ANRS Codex: first 100 enrolled patients < usVL < usVL < 4 - At 12 months: among the 16 with a sample, only 8 have a usVL still < 4 RNA copies/mL

The CD4 T cells The decrease of the CD4 T cell count In the US Army cohort, the CD4 T cell counts decreased in 6 / 25 controllers (Okulicz et al JID 2009) In the French Observatory, two-third of the controllers had a negative slope of their CD4 T cell count Loss of 14 [-12 ; -16] CD4/year In the French ANRS CO21 Cohort: –At enrollment, the median CD4 T cell count was 752/mm3 [IQR : ] –10 confirmed « immunological escape » = two consecutive CD4 T cell counts < 350/mm3 –8 are treated by ART

What is driving the CD4 T cell decrease in Controllers ? The virus Immune activation Immunosenescence

CD4 T cell decrease is related to HIV Possible role of blips –  1 blip was associated with a negative slope of CD4 T cell counts in controllers of the French Observatory (Boufassa et al. PLoS One 2011)

The virus is involved in some HIC Detectable VL in 34/35 samples

What is driving the CD4 T cell decrease in Controllers ? The virus –Yes, but not in all patients –Role of blips –Very slow CD4 T cell recovery in 36 HIV controllers on ART from 4 cohorts Immune activation Immunosenescence (Sedaghat et al CID 2009)

CD4 T cell decrease is related to immune activation 12 Hunt P et al. JID 2008 HIV controllers have higher activation of CD4 and CD8 T cells than HIV-

S Potter J Virol 2007

Correlation between the CD4 T cell count in controllers and CD4 and CD8 T cell activation (P Hunt JID 2008 )

Immune activation in HIV controllers has several causes Appay et al. 2008

16 Microbial translocation is higher in controllers than in healthy donnors (collaboration ANRS EP36) Brenchley J et al. Nat Med 2006 Microbial translocation is correlated with CD8 T cell activation Hunt et al JID 2008

A consequence of chronic inflammation: Cardiovascular risk seems to be increased in HIV controllers Hsue P, AIDS 2009 AIDS 2012 Consequences of immune activation seem to be present in HIV Controllers

What is driving the CD4 T cell decrease in Controllers ? The virus Immune activation –Microbial translocation –Anti-HIV immune response –Other unknown mechanisms Immunosenescence –Decreased lymphopoiesis in controllers with low CD4 T cell counts (Sauce et al. Blood 2011)

But real life is not simple …

Spontaneous fluctuations of CD4 T cell counts are common in HIV controllers Even with periods below 500 /mm3, with or without a clear relation with viral blips

Should we treat HIV controllers ? Two major points –It is not an emergency –The patient’s opinion is essential > observance If the CD4 T cell decrease is significant and durable with/without viral replication : YES with ART If the CD4 T cell count is stable without blips: NO (situation of functional cure ?) In the other situations...

Should we treat HIV controllers ? Two major points –It is not an emergency –The patient’s opinion is essential > observance In the other situations: To target immune activation is a major goal and a suject of research : Combination of hydroxychloroquine, statine, low dose steroids, etc... WITH ART We need markers which could help the clinician –Markers of immune activation on CD4 / CD8 T cells –Biomarkers of inflammation –Viral DNA, us RNA...

INSERM U1012 Olivier Lambotte Camille Lécuroux Isabelle Girault Stéphane Hua Christine Bourgeois Alain Venet Sandie Gérard Nicolas Noel INSERM U1018 Faroudy Boufassa Laurence Meyer CHU Bicêtre Cécile Goujard Jean-François Delfraissy Katia Bourdic Institut Pasteur Asier Saez-Cirion Gianfranco Pancino USA Peter Hunt Florencia Pereyra CHU Necker Christine Rouzioux Patients and clinicians !! Cohorte ANRS CO21

Profil transcriptionnel des infections par le SIV pathogènes et non pathogènes Manches et al. JCI 2009

Reduction of Immune Activation with Chloroquine Therapy during Chronic HIV Infection (Murray et al. J Virol 2010)